Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics ( GFCH )

IF 9.4 1区医学 Q1 HEMATOLOGY

American Journal of Hematology Pub Date : 2026-10-05 DOI:10.1002/ajh.70499

Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse

{"title":"Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics ( GFCH )","authors":"Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse","doi":"10.1002/ajh.70499","DOIUrl":null,"url":null,"abstract":"Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a comprehensive review of chromosomal abnormalities associated with drug sensitivity and resistance in hematological disorders. This work highlights the emergence of alteration‐driven therapy, with certain agents (e.g., tyrosine kinase inhibitors, menin inhibitors, venetoclax) used across entities sharing common molecular lesions, while others remain disease‐specific, such as in Helicobacter pylori –associated lymphomas.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"11 1","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ajh.70499","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a comprehensive review of chromosomal abnormalities associated with drug sensitivity and resistance in hematological disorders. This work highlights the emergence of alteration‐driven therapy, with certain agents (e.g., tyrosine kinase inhibitors, menin inhibitors, venetoclax) used across entities sharing common molecular lesions, while others remain disease‐specific, such as in Helicobacter pylori –associated lymphomas.

查看原文本刊更多论文

血液学恶性肿瘤的染色体异常、药物敏感性和耐药性：法语国家血液学细胞遗传学（GFCH）的综合综述

染色体异常对血液系统恶性肿瘤具有重要的临床影响，特别是在治疗策略方面。为了保存和巩固这一快速发展领域的基础知识，法语国家血液细胞遗传学小组（Groupe Francophone de cytogacimacatisque， GFCH）对血液学疾病中与药物敏感性和耐药性相关的染色体异常进行了全面回顾。这项工作强调了改变驱动疗法的出现，某些药物（如酪氨酸激酶抑制剂、menin抑制剂、venetoclax）在具有共同分子病变的实体中使用，而其他药物仍然是疾病特异性的，如幽门螺杆菌相关的淋巴瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Hematology 医学-血液学

CiteScore

15.70

自引率

3.90%

发文量

363

审稿时长

3-6 weeks

期刊介绍： The American Journal of Hematology offers extensive coverage of experimental and clinical aspects of blood diseases in humans and animal models. The journal publishes original contributions in both non-malignant and malignant hematological diseases, encompassing clinical and basic studies in areas such as hemostasis, thrombosis, immunology, blood banking, and stem cell biology. Clinical translational reports highlighting innovative therapeutic approaches for the diagnosis and treatment of hematological diseases are actively encouraged.The American Journal of Hematology features regular original laboratory and clinical research articles, brief research reports, critical reviews, images in hematology, as well as letters and correspondence.